Patrick C. McGowan

Find an error

Name:
Organization: University of Leeds , England
Department: School of Chemistry
Title: Reader(PhD)

TOPICS

Co-reporter:Stephanie. J. Lucas, Rianne M. Lord, Aida M. Basri, Simon J. Allison, Roger M. Phillips, A. John Blacker and Patrick C. McGowan  
Dalton Transactions 2016 vol. 45(Issue 16) pp:6812-6815
Publication Date(Web):17 Feb 2016
DOI:10.1039/C6DT00186F
Here in, we report the cytotoxicity of both rhodium and iridium functionalised Cp* analogues of the [Cp*MCl2]2 dimers. The functionalised dimers contain a hydroxy tethered arm of differing carbon length. These show promising IC50 values when tested against HT-29, A2780 and cisplatin-resistant A2780cis human cancer cell lines, with the cytotoxicity improving proportionally with an increase in carbon tether length of the Cp* ring. The most promising results are seen for the 14-carbon Cp* tethered rhodium (2d) and iridium (3b) complexes, which show up to a 24-fold increase in IC50 compared to the unfunctionalised [Cp*MCl2]2 dimer. All complexes were potent inhibitors of purified thioredoxin reductase suggesting that disruption of cellular anti-oxidant function is one potential mechanism of action.
Co-reporter:Rianne M. Lord, Simon J. Allison, Karen Rafferty, Laura Ghandhi, Christopher M. Pask and Patrick C. McGowan  
Dalton Transactions 2016 vol. 45(Issue 33) pp:13196-13203
Publication Date(Web):04 Jul 2016
DOI:10.1039/C6DT01464J
This report presents the first known p-cymene ruthenium quinaldamide complexes which are stabilised by a hydrogen-bridging atom, [{(p-cym)RuIIX(N,N)}{H+}{(N,N)XRuII(p-cym)}][PF6] (N,N = functionalised quinaldamide and X = Cl or Br). These complexes are formed by a reaction of [p-cymRu(μ-X)2]2 with a functionalised quinaldamide ligand. When filtered over NH4PF6, and under aerobic conditions the equilibrium of NH4PF6 ⇔ NH3 + HPF6 enables incorporation of HPF6 and the stabilisation of two monomeric ruthenium complexes by a bridging H+, which are counter-balanced by a PF6 counterion. X-ray crystallographic analysis is presented for six new structures with O⋯O distances of 2.420(4)–2.448(15) Å, which is significant for strong hydrogen bonds. Chemosensitivity studies against HCT116, A2780 and cisplatin-resistant A2780cis human cancer cells showed the ruthenium complexes with a bromide ancillary ligand to be more potent than those with a chloride ligand. The 4′-fluoro compounds show a reduction in potency for both chloride and bromide complexes against all cell lines, but an increase in selectivity towards cancer cells compared to non-cancer ARPE-19 cells, with a selectivity index >1. Mechanistic studies showed a clear correlation between IC50 values and induction of cell death by apoptosis.
Co-reporter:Rianne M. Lord, Stacey M. Lord, Christopher M. Pask, Patrick C. McGowan
Polyhedron 2016 Volume 116() pp:136-143
Publication Date(Web):25 September 2016
DOI:10.1016/j.poly.2016.04.017
Reactions have been carried out using the titanium(IV) precursors TiCl4 and Ti(OiPr)4, with addition of two equivalents of a functionalized picolinamide ligand. The reactions with TiCl4 led to the formation of either a mononuclear titanium species, [Ti(N,O)Cl2X2] or a dinuclear titanium species [Ti(N,O)X3]2[μ-O] (X = OMe or Cl), with incorporation of one picolinamide ligand. The ligand is bound to the titanium centre as the protonated amide. The reactions with Ti(OiPr)4 resulted in the formation of mononuclear titanium bis-picolinamide species [Ti(N,O)2(OiPr)2], and also dinuclear and trinuclear products, [(N,O)Ti(OiPr)2][μ-OiPr]2 and [(N,O)Ti(OiPr)2]2[μ-OiPr]2[(OiPr)2Ti][μ3-O] respectively. In these cases the picolinamide ligand was found to be deprotonated and bound to the titanium as the iminolate. These molecules have been characterized by X-ray crystallographic analysis and structural characteristics are discussed.This report focuses on the unusual structural motifs of mononuclear, dinuclear and trinuclear titanium picolinamide complexes from the reactions with TiCl4 and Ti(OiPr)4 precursors.
Co-reporter:Rianne M. Lord; Andrew J. Hebden; Christopher M. Pask; Imogen R. Henderson; Simon J. Allison; Samantha L. Shepherd; Roger M. Phillips
Journal of Medicinal Chemistry 2015 Volume 58(Issue 12) pp:4940-4953
Publication Date(Web):April 23, 2015
DOI:10.1021/acs.jmedchem.5b00455
A series of ruthenium and iridium complexes have been synthesized and characterized with 20 novel crystal structures discussed. The library of β-ketoiminato complexes has been shown to be active against MCF-7 (human breast carcinoma), HT-29 (human colon carcinoma), A2780 (human ovarian carcinoma), and A2780cis (cisplatin-resistant human ovarian carcinoma) cell lines, with selected complexes’ being more than three times as active as cisplatin against the A2780cis cell line. Selected complexes were also tested against the noncancerous ARPE-19 (retinal pigment epithelial cells) cell line, in order to evaluate the complexes selectivity for cancer cells. Complexes have also been shown to be highly active under hypoxic conditions, with the activities of some complexes increasing with a decrease in O2 concentration. The enzyme thioredoxin reductase is overexpressed in cancer cells, and complexes reported herein have the advantage of inhibiting this enzyme, with IC50 values measured in the nanomolar range. The anticancer activity of these complexes was further investigated to determine whether activity is due to effects on cellular growth or cell survival. The complexes were found to induce significant levels of cancer cell death by apoptosis with levels induced correlating closely with activity in chemosensitivity studies. As a possible cause of cell death, the ability of the complexes to induce damage to cellular DNA was also assessed. The complexes failed to induce double-strand DNA breaks or DNA cross-linking but induced significant levels of single-strand DNA breaks, indicating a mechanism of action different from that of cisplatin.
Co-reporter:A. Rodríguez-Bárzano, R. M. Lord, A. M. Basri, R. M. Phillips, A. J. Blacker and P. C. McGowan  
Dalton Transactions 2015 vol. 44(Issue 7) pp:3265-3270
Publication Date(Web):05 Jan 2015
DOI:10.1039/C4DT02748E
The complexes [RuCp*(PP)Cl] (Cp* = C5Me5; [1], PP = dppm; [4], PP = Xantphos), [RuCp#(PP)Cl] (Cp# = C5Me4(CH2)5OH; [2], PP = dppm; [5], PP = Xantphos) and [RuCp*(dppm)(CH3CN)][SbF6] [3] were synthesized and evaluated in vitro as anticancer agents. Compounds 1–3 gave nanomolar IC50 values against normoxic A2780 and HT-29 cell lines, and were also tested against hypoxic HT-29 cells, maintaining their high activity. Complex 3 yielded an IC50 value of 0.55 ± 0.03 μM under a 0.1% O2 concentration.
Co-reporter:Carlo Sambiagio, Stephen P. Marsden, A. John Blacker and Patrick C. McGowan  
Chemical Society Reviews 2014 vol. 43(Issue 10) pp:3525-3550
Publication Date(Web):03 Mar 2014
DOI:10.1039/C3CS60289C
Cu-catalysed arylation reactions devoted to the formation of C–C and C–heteroatom bonds (Ullmann-type couplings) have acquired great importance in the last decade. This review discusses the history and development of coupling reactions between aryl halides and various classes of nucleophiles, focusing mostly on the different mechanisms proposed through the years. Selected mechanistic investigations are treated more in depth than others. For example, evidence in favour or against radical mechanisms is discussed. Cu(I) and Cu(III) complexes involved in the Ullmann reaction and N/O selectivity in aminoalcohol arylation are discussed. A separate section has been dedicated to the synthesis of heterocyclic rings through intramolecular couplings. Finally, recent developments in green chemistry for these reactions, such as reactions in aqueous media and heterogeneous catalysis, have also been reviewed.
Co-reporter:Zahra Almodares, Stephanie J. Lucas, Benjamin D. Crossley, Aida M. Basri, Christopher M. Pask, Andrew J. Hebden, Roger M. Phillips, and Patrick C. McGowan
Inorganic Chemistry 2014 Volume 53(Issue 2) pp:727-736
Publication Date(Web):January 7, 2014
DOI:10.1021/ic401529u
Novel rhodium, iridium, and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anticancer agents. The complexes show promising cytotoxicities, with the presence, position, and number of halides having a significant effect on the corresponding IC50 values. One ruthenium complex was found to be more cytotoxic than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively, and it remains active with MCF-7 cells even under hypoxic conditions, making it a promising candidate for in vivo studies.
Co-reporter:Andrea Rodríguez-Bárzano;Joel D. A. Fonseca;A. John Blacker
European Journal of Inorganic Chemistry 2014 Volume 2014( Issue 11) pp:1974-1983
Publication Date(Web):
DOI:10.1002/ejic.201400117

Abstract

A range of ruthenium-arene compounds with chloride, bromide or iodide ligands were prepared and tested as catalysts for the homogeneous redox neutral alkylation of tert-butylamine with phenethyl alcohol, and compared to the previously reported catalyst [RuCl2(p-cymene)]2, in the presence of the diphosphine 1,1′-bis(diphenylphosphino)ferrocene (dppf). The best catalytic activities were obtained with ruthenium iodide compounds. The formation of either [RuX(p-cymene)(dppf)][X] or [(RuX2(p-cymene))2(dppf)] (X = halide) under the catalytic conditions employed was investigated.

Co-reporter:Weian Zhang;Lizhi Hong
Macromolecular Chemistry and Physics 2014 Volume 215( Issue 9) pp:900-905
Publication Date(Web):
DOI:10.1002/macp.201400012
Co-reporter:Rianne M. Lord;Dr. James J. Mannion;Dr. Andrew J. Hebden;Adi E. Nako;Dr. Benjamin D. Crossley;Max W. McMullon;Felix D. Janeway;Dr. Roger M. Phillips;Dr. Patrick C. McGowan
ChemMedChem 2014 Volume 9( Issue 6) pp:1136-1139
Publication Date(Web):
DOI:10.1002/cmdc.201402019

Abstract

Group IV metal complexes have previously shown promise as novel anticancer agents. Here, we discuss the mechanistic and cytotoxic nature of a series of group IV β-diketonate coordination complexes. Clear evidence that the ligands are exchangeable on the metal centre and that the β-diketonate ligands can act as potential drug delivery vehicles of the group IV metal ions was obtained. When evaluated for the cytotoxicity against human colon adenocarcinoma (HT-29) and human breast adenocarcinoma (MCF-7) cell lines, a general trend of decreasing potency down the group IV metals was observed. The most promising results obtained were for the hafnium complexes, with the tris diphenyl β-diketonate hafnium complex exhibiting IC50 values of 4.9±0.9 μM and 3.2±0.3 μM against HT-29 and MCF-7, respectively, which are comparable with the activity of cisplatin against the same cell lines. This tri β-diketonate hafnium complex is the first to show potent in vitro cytotoxic activity. The results reported show that ligand design has a significant effect on the cytotoxic potential of the complexes, and that these group IV complexes warrant further evaluation as novel metal-containing anticancer agents.

Co-reporter:Carlo Sambiagio;Dr. Rachel H. Munday; Stephen P. Marsden; A. John Blacker;Dr. Patrick C. McGowan
Chemistry - A European Journal 2014 Volume 20( Issue 52) pp:17606-17615
Publication Date(Web):
DOI:10.1002/chem.201404275

Abstract

The use of picolinic acid amide derivatives as an effective family of bidentate ligands for copper-catalysed aryl ether synthesis is reported. A fluorine-substituted ligand gave good results in the synthesis of a wide range of aryl ethers. Even bulky phenols, known to be very challenging substrates, were shown to react with aryl iodides with excellent yields using these ligands. At the end of the reaction, the first examples of end-of-life Cu species were isolated and identified as CuII complexes with several of the anionic ligands tested. A preliminary mechanistic investigation is reported that suggests that the substituents on the ligands might have a crucial role in determining the redox properties of the metal centre and, consequently, its efficacy in the coupling process. An understanding of these effects is important for the development of new efficient and tunable ligands for copper-based chemistry.

Co-reporter:Stephanie J. Lucas, Benjamin D. Crossley, Alan J. Pettman, Antony D. Vassileiou, Thomas E. O. Screen, A. John Blacker and Patrick C. McGowan  
Chemical Communications 2013 vol. 49(Issue 49) pp:5562-5564
Publication Date(Web):07 May 2013
DOI:10.1039/C3CC42550A
This paper provides a viable, reproducible and robust method for immobilising hydroxyl tethered iridium–rhodium complexes. The materials have been shown to be both effective and recyclable in the process of catalytic transfer hydrogenation with minimal metal leaching.
Co-reporter:Andrea Rodríguez-Bárzano, A. John Blacker and Patrick C. McGowan  
Dalton Transactions 2013 vol. 42(Issue 48) pp:16669-16671
Publication Date(Web):09 Oct 2013
DOI:10.1039/C3DT52747F
Reactions of [RuCp*Cl2]2 with dibenzoylmethane and triethylamine, in either dichloromethane or toluene, produced the complexes [RuCl(η6-C5Me4CH2)(PhCOCCOPh)] (1) and [RuCl3(η6-C5Me4CH2)][RuCp*(C6H5CH3)] (2) respectively under mild conditions. Both compounds 1 and 2 are examples of an unusual tetramethylfulvene-ruthenium structure, obtained by deprotonation of the pentamethylcyclopentadienyl ligand, and were characterised by single-crystal X-ray diffraction.
Co-reporter:Stephanie J. Lucas, Rianne M. Lord, Rachel L. Wilson, Roger M. Phillips, Visuvanathar Sridharan and Patrick C. McGowan  
Dalton Transactions 2012 vol. 41(Issue 45) pp:13800-13802
Publication Date(Web):14 Sep 2012
DOI:10.1039/C2DT32104A
Several Ru-arene and Ir–Cp* complexes have been prepared incorporating (N,N), (N,O) and (O,O) coordinating bidentate ligands and have been found to be active against both HT-29 and MCF-7 cell lines. By incorporating a biologically active ligand into a metal complex the anti-cancer activity is increased.
Co-reporter:Robert O. MacRae;Christopher M. Pask;Lucy K. Burdsall;Richard S. Blackburn;Christopher M. Rayner
Angewandte Chemie International Edition 2011 Volume 50( Issue 1) pp:
Publication Date(Web):
DOI:10.1002/anie.201006804
Co-reporter:Robert O. MacRae;Christopher M. Pask;Lucy K. Burdsall;Richard S. Blackburn;Christopher M. Rayner
Angewandte Chemie International Edition 2011 Volume 50( Issue 1) pp:291-294
Publication Date(Web):
DOI:10.1002/anie.201004920
Co-reporter:Robert O. MacRae;Christopher M. Pask;Lucy K. Burdsall;Richard S. Blackburn;Christopher M. Rayner
Angewandte Chemie 2011 Volume 123( Issue 1) pp:305-308
Publication Date(Web):
DOI:10.1002/ange.201004920
Co-reporter:Robert O. MacRae;Christopher M. Pask;Lucy K. Burdsall;Richard S. Blackburn;Christopher M. Rayner
Angewandte Chemie 2011 Volume 123( Issue 1) pp:
Publication Date(Web):
DOI:10.1002/ange.201006804
Co-reporter:Tian Tang, Tanapak Metanawin, Andrew Hebden, Patrick McGowan and Xiao-Song Wang  
Chemical Communications 2010 vol. 46(Issue 36) pp:6663-6665
Publication Date(Web):17 Jun 2010
DOI:10.1039/C0CC01235A
Manipulation of metal atom nucleation and particle growth in solution is virtually unexplored, but highly sought after for the creation of functional materials and rational design of supramolecular structures. We therefore decided to explore this area through the self-assembly of block copolymer micelles and Pd atoms without using a chemical reduction reaction.
Co-reporter:Sabine H. van Rijt ; Andrew J. Hebden ; Thakshila Amaresekera ; Robert J. Deeth ; Guy J. Clarkson ; Simon Parsons ; Patrick C. McGowan ;Peter J. Sadler
Journal of Medicinal Chemistry 2009 Volume 52(Issue 23) pp:7753-7764
Publication Date(Web):September 30, 2009
DOI:10.1021/jm900731j
We show that the binding mode adopted by picolinamide derivatives in organometallic OsII and RuII half-sandwich complexes can lead to contrasting cancer cell cytotoxicity. N-Phenyl picolinamide derivatives (XY) in OsII (1, 3−5, 7, 9) and RuII (2, 6, 8, 10) complexes [(η6-arene)(Os/Ru)(XY)Cl]n+, where arene = p-cymene (1−8, 10) or biphenyl (9), can act as N,N- or N,O-donors. Electron-withdrawing substituents on the phenyl ring resulted in N,N-coordination and electron-donating substituents in N,O-coordination. Dynamic interconversion between N,O and N,N configurations can occur in solution and is time- and temperature- (irreversible) as well as pH-dependent (reversible). The neutral N,N-coordinated compounds (1−5 and 9) hydrolyzed rapidly (t1/2 ≤ min), exhibited significant (32−70%) and rapid binding to guanine, but no binding to adenine. The N,N-coordinated compounds 1, 3, 4, and 9 exhibited significant activity against colon, ovarian, and cisplatin-resistant ovarian human cancer cell lines (3 ≫ 4 > 1 > 9). In contrast, N,O-coordinated complexes 7 and 8 hydrolyzed slowly, did not bind to guanine or adenine, and were nontoxic.
Co-reporter:Kenneth D. Camm, Ahmed El-Sokkary, Andrew L. Gott, Peter G. Stockley, Tamara Belyaeva and Patrick C. McGowan  
Dalton Transactions 2009 (Issue 48) pp:10914-10925
Publication Date(Web):16 Nov 2009
DOI:10.1039/B918902E
A number of new ruthenium compounds have been synthesised, isolated and characterised, which exhibit excellent cytotoxicity against a number of different human tumour cell lines including a defined cisplatin resistant cell line and colon cancer cell lines. Addition of hydrophobic groups to the ruthenium molecules has a positive effect on the cytotoxicity values. Evidence is provided that, after incubation of a ruthenium compound with a 46 mer oligonucleotide duplex and subsequent nuclease treatment, ruthenium is bound to a guanine residue.
Co-reporter:Patrick C. McGowan, Claire N. Temple
Inorganica Chimica Acta 2009 Volume 362(Issue 9) pp:3165-3171
Publication Date(Web):1 July 2009
DOI:10.1016/j.ica.2009.02.015
A series of 1,4,7-triazacyclononane derivatives of Fe(II) been investigated where changing the functionality of a pendant group has created different Fe(II) coordination environments. New examples of triazacyclononane supported iron dibromide complexes are presented as well as an iron complex bearing a novel 1,4,7-triazacyclononane containing a thiophene pendant-arm.A series of 1,4,7-triazacyclononane derivatives of Fe(II) been investigated where changing the functionality of a pendant group has created different Fe(II) coordination environments. New examples of triazacyclononane supported iron dibromide complexes are presented as well as an iron complex bearing a novel 1,4,7-triazacyclononane containing a thiophene pendant-arm.
Co-reporter:Andrew L. Gott, Patrick C. McGowan and Thomas J. Podesta  
Dalton Transactions 2008 (Issue 28) pp:3729-3738
Publication Date(Web):04 Jun 2008
DOI:10.1039/B804572K
Pendant arm macrocycles derived from 1,4,7-triazacyclononane were reacted with RuHCl(CO)(PPh3)3 and RuHCl(PPh3)3 to yield air-stable cationic ruthenium hydrides that were characterised by a variety of techniques, including X-ray crystallography. Protonation of the metal hydride complexes with a proton source yielded η2-dihydrogen complexes. The lifetime of the dihydrogen ligand was effected by a judicious choice of ancillary ligands.
Co-reporter:Olivia R. Allen, Richard J. Knox and Patrick C. McGowan  
Dalton Transactions 2008 (Issue 39) pp:5293-5295
Publication Date(Web):18 Aug 2008
DOI:10.1039/B812244J
New neutral and ionic functionalised zirconocene dichloride compounds have been isolated and characterised. The ionic zirconocene exhibits excellent cytotoxicity against a range of human tumour cell lines, which represents the first active anticancer zirconocene dichloride compound.
Co-reporter:Andrew L. Gott, Patrick C. McGowan and Claire N. Temple
Organometallics 2008 Volume 27(Issue 12) pp:2852-2860
Publication Date(Web):May 21, 2008
DOI:10.1021/om800180a
A number of κ1- and κ3-triazacyclononane RhI, Ir1, RhIII, and IrIII derivatives have been synthesized and characterized, with conversion from κ1-triazacyclononane complexes to κ3-derivatives. The results of the catalytic studies show that the Rh(I) and Ir(I) complexes polymerize phenylacetylene more effectively than [M(COD)(μ-Cl)]2 (M = Rh and Ir).
Co-reporter:Andrew L. Gott, Patrick C. McGowan and Thomas J. Podesta
Dalton Transactions 2008(Issue 28) pp:NaN3738-3738
Publication Date(Web):2008/06/04
DOI:10.1039/B804572K
Pendant arm macrocycles derived from 1,4,7-triazacyclononane were reacted with RuHCl(CO)(PPh3)3 and RuHCl(PPh3)3 to yield air-stable cationic ruthenium hydrides that were characterised by a variety of techniques, including X-ray crystallography. Protonation of the metal hydride complexes with a proton source yielded η2-dihydrogen complexes. The lifetime of the dihydrogen ligand was effected by a judicious choice of ancillary ligands.
Co-reporter:Carlo Sambiagio, Stephen P. Marsden, A. John Blacker and Patrick C. McGowan
Chemical Society Reviews 2014 - vol. 43(Issue 10) pp:NaN3550-3550
Publication Date(Web):2014/03/03
DOI:10.1039/C3CS60289C
Cu-catalysed arylation reactions devoted to the formation of C–C and C–heteroatom bonds (Ullmann-type couplings) have acquired great importance in the last decade. This review discusses the history and development of coupling reactions between aryl halides and various classes of nucleophiles, focusing mostly on the different mechanisms proposed through the years. Selected mechanistic investigations are treated more in depth than others. For example, evidence in favour or against radical mechanisms is discussed. Cu(I) and Cu(III) complexes involved in the Ullmann reaction and N/O selectivity in aminoalcohol arylation are discussed. A separate section has been dedicated to the synthesis of heterocyclic rings through intramolecular couplings. Finally, recent developments in green chemistry for these reactions, such as reactions in aqueous media and heterogeneous catalysis, have also been reviewed.
Co-reporter:Tian Tang, Tanapak Metanawin, Andrew Hebden, Patrick McGowan and Xiao-Song Wang
Chemical Communications 2010 - vol. 46(Issue 36) pp:NaN6665-6665
Publication Date(Web):2010/06/17
DOI:10.1039/C0CC01235A
Manipulation of metal atom nucleation and particle growth in solution is virtually unexplored, but highly sought after for the creation of functional materials and rational design of supramolecular structures. We therefore decided to explore this area through the self-assembly of block copolymer micelles and Pd atoms without using a chemical reduction reaction.
Co-reporter:Andrea Rodríguez-Bárzano, A. John Blacker and Patrick C. McGowan
Dalton Transactions 2013 - vol. 42(Issue 48) pp:NaN16671-16671
Publication Date(Web):2013/10/09
DOI:10.1039/C3DT52747F
Reactions of [RuCp*Cl2]2 with dibenzoylmethane and triethylamine, in either dichloromethane or toluene, produced the complexes [RuCl(η6-C5Me4CH2)(PhCOCCOPh)] (1) and [RuCl3(η6-C5Me4CH2)][RuCp*(C6H5CH3)] (2) respectively under mild conditions. Both compounds 1 and 2 are examples of an unusual tetramethylfulvene-ruthenium structure, obtained by deprotonation of the pentamethylcyclopentadienyl ligand, and were characterised by single-crystal X-ray diffraction.
Co-reporter:Stephanie. J. Lucas, Rianne M. Lord, Aida M. Basri, Simon J. Allison, Roger M. Phillips, A. John Blacker and Patrick C. McGowan
Dalton Transactions 2016 - vol. 45(Issue 16) pp:NaN6815-6815
Publication Date(Web):2016/02/17
DOI:10.1039/C6DT00186F
Here in, we report the cytotoxicity of both rhodium and iridium functionalised Cp* analogues of the [Cp*MCl2]2 dimers. The functionalised dimers contain a hydroxy tethered arm of differing carbon length. These show promising IC50 values when tested against HT-29, A2780 and cisplatin-resistant A2780cis human cancer cell lines, with the cytotoxicity improving proportionally with an increase in carbon tether length of the Cp* ring. The most promising results are seen for the 14-carbon Cp* tethered rhodium (2d) and iridium (3b) complexes, which show up to a 24-fold increase in IC50 compared to the unfunctionalised [Cp*MCl2]2 dimer. All complexes were potent inhibitors of purified thioredoxin reductase suggesting that disruption of cellular anti-oxidant function is one potential mechanism of action.
Co-reporter:Olivia R. Allen, Richard J. Knox and Patrick C. McGowan
Dalton Transactions 2008(Issue 39) pp:NaN5295-5295
Publication Date(Web):2008/08/18
DOI:10.1039/B812244J
New neutral and ionic functionalised zirconocene dichloride compounds have been isolated and characterised. The ionic zirconocene exhibits excellent cytotoxicity against a range of human tumour cell lines, which represents the first active anticancer zirconocene dichloride compound.
Co-reporter:A. Rodríguez-Bárzano, R. M. Lord, A. M. Basri, R. M. Phillips, A. J. Blacker and P. C. McGowan
Dalton Transactions 2015 - vol. 44(Issue 7) pp:NaN3270-3270
Publication Date(Web):2015/01/05
DOI:10.1039/C4DT02748E
The complexes [RuCp*(PP)Cl] (Cp* = C5Me5; [1], PP = dppm; [4], PP = Xantphos), [RuCp#(PP)Cl] (Cp# = C5Me4(CH2)5OH; [2], PP = dppm; [5], PP = Xantphos) and [RuCp*(dppm)(CH3CN)][SbF6] [3] were synthesized and evaluated in vitro as anticancer agents. Compounds 1–3 gave nanomolar IC50 values against normoxic A2780 and HT-29 cell lines, and were also tested against hypoxic HT-29 cells, maintaining their high activity. Complex 3 yielded an IC50 value of 0.55 ± 0.03 μM under a 0.1% O2 concentration.
Co-reporter:Stephanie J. Lucas, Rianne M. Lord, Rachel L. Wilson, Roger M. Phillips, Visuvanathar Sridharan and Patrick C. McGowan
Dalton Transactions 2012 - vol. 41(Issue 45) pp:NaN13802-13802
Publication Date(Web):2012/09/14
DOI:10.1039/C2DT32104A
Several Ru-arene and Ir–Cp* complexes have been prepared incorporating (N,N), (N,O) and (O,O) coordinating bidentate ligands and have been found to be active against both HT-29 and MCF-7 cell lines. By incorporating a biologically active ligand into a metal complex the anti-cancer activity is increased.
Co-reporter:Kenneth D. Camm, Ahmed El-Sokkary, Andrew L. Gott, Peter G. Stockley, Tamara Belyaeva and Patrick C. McGowan
Dalton Transactions 2009(Issue 48) pp:NaN10925-10925
Publication Date(Web):2009/11/16
DOI:10.1039/B918902E
A number of new ruthenium compounds have been synthesised, isolated and characterised, which exhibit excellent cytotoxicity against a number of different human tumour cell lines including a defined cisplatin resistant cell line and colon cancer cell lines. Addition of hydrophobic groups to the ruthenium molecules has a positive effect on the cytotoxicity values. Evidence is provided that, after incubation of a ruthenium compound with a 46 mer oligonucleotide duplex and subsequent nuclease treatment, ruthenium is bound to a guanine residue.
Co-reporter:Stephanie J. Lucas, Benjamin D. Crossley, Alan J. Pettman, Antony D. Vassileiou, Thomas E. O. Screen, A. John Blacker and Patrick C. McGowan
Chemical Communications 2013 - vol. 49(Issue 49) pp:NaN5564-5564
Publication Date(Web):2013/05/07
DOI:10.1039/C3CC42550A
This paper provides a viable, reproducible and robust method for immobilising hydroxyl tethered iridium–rhodium complexes. The materials have been shown to be both effective and recyclable in the process of catalytic transfer hydrogenation with minimal metal leaching.
Co-reporter:Rianne M. Lord, Simon J. Allison, Karen Rafferty, Laura Ghandhi, Christopher M. Pask and Patrick C. McGowan
Dalton Transactions 2016 - vol. 45(Issue 33) pp:NaN13203-13203
Publication Date(Web):2016/07/04
DOI:10.1039/C6DT01464J
This report presents the first known p-cymene ruthenium quinaldamide complexes which are stabilised by a hydrogen-bridging atom, [{(p-cym)RuIIX(N,N)}{H+}{(N,N)XRuII(p-cym)}][PF6] (N,N = functionalised quinaldamide and X = Cl or Br). These complexes are formed by a reaction of [p-cymRu(μ-X)2]2 with a functionalised quinaldamide ligand. When filtered over NH4PF6, and under aerobic conditions the equilibrium of NH4PF6 ⇔ NH3 + HPF6 enables incorporation of HPF6 and the stabilisation of two monomeric ruthenium complexes by a bridging H+, which are counter-balanced by a PF6 counterion. X-ray crystallographic analysis is presented for six new structures with O⋯O distances of 2.420(4)–2.448(15) Å, which is significant for strong hydrogen bonds. Chemosensitivity studies against HCT116, A2780 and cisplatin-resistant A2780cis human cancer cells showed the ruthenium complexes with a bromide ancillary ligand to be more potent than those with a chloride ligand. The 4′-fluoro compounds show a reduction in potency for both chloride and bromide complexes against all cell lines, but an increase in selectivity towards cancer cells compared to non-cancer ARPE-19 cells, with a selectivity index >1. Mechanistic studies showed a clear correlation between IC50 values and induction of cell death by apoptosis.
2-Buten-1-one, 3-hydroxy-1-(4-methylphenyl)-
Ethanone, 1-[3-(4-nitrophenoxy)phenyl]-
2-Buten-1-one, 1-(4-bromophenyl)-3-hydroxy-
Piperidine, 1-methyl-4-[3-(triphenylplumbyl)-1,4-cyclopentadien-1-yl]-
1,4-Cyclohexadiene-1-acetic acid
Cyclohexanecarboxamide, N-(4-methoxyphenyl)-
2,4-Cyclopentadiene-1-ethanamine
6bH-2a,4a,6a-Triazacyclopenta[cd]pentalene, hexahydro-
Piperidine, 4-(2-cyclopentadienylethyl)-1-methyl-
Sodium, [1-(1-methyl-4-piperidinyl)-2,4-cyclopentadien-1-yl]-